Human Immunodeficiency Virus Reverse Transcriptase
Stuart LeGrice ยท Matthias Gotte
แแแ. 2013 ยท Springer Science & Business Media
แแแฌแแแแ
361
แแแแ แแ
reportแ แแแขแแแแแแ แแ แแแแแฎแแแแแแ แแแฃแแแกแขแฃแ แแแแแแ ย แจแแแขแงแแแ แแแขแ
แแ แแแฌแแแแแก แจแแกแแฎแแ
The Reverse Transcriptase (RT) of Human Immunodeficiency Virus Type 1 (HIV-1) arguably ranks amongst one of the most extensively studied retroviral enzymes. Heterologous expression and purification of HIV-1 RT in the early eighties, approval of the first nucleoside analogue RT inhibitor (NRTI) in 1987, discovery of resistance to RT inhibitors, approval of the first non-nucleoside analogue RT inhibitor (NNRTI) in 1996 and the various crystal structures of RT with and without bound substrate(s) and/or inhibitors represent only a few of the important milestones that describe the a bench-to-bedside success in the continuing effort to combat HIV-1 infection and its consequences. Nucleoside and nonnucleoside RT inhibitors remain important components in frequently used drug regimens to treat the infection. RT inhibitors also play important roles in recently validated strategies to prevent transmission of the virus. The relevance of HIV-1 RT as a drug target has simultaneously triggered interest in basic research studies aimed at providing a more detailed understanding of interactions between proteins, nucleic acids, and small molecule ligands in general terms. In light of the ever-growing knowledge on structure and function of HIV-1 RT, this enzyme serves as a valuable โmodel systemโ in efforts to develop novel experimental tools and to explain biochemical processes. This monograph is designed to provide an overview of important aspects in past and current HIV-1 RT research, with focus on mechanistic aspects and translation of knowledge into drug discovery and development. The first section includes chapters with emphasis placed on the coordination of the RT-associated DNA polymerase and ribonuclease H (RNase H) activities. The second covers mechanisms of action and future perspectives associated with NRTIs and NNRTIs, while the third section includes chapters focusing on novel strategies to target the RT enzyme. Chapters of the final part are intended to discuss mechanisms involved in HIV variability and the development of drug resistance. We hope that these contributions will stimulate interest, and encourage research aimed at the development of novel RT inhibitors. The lack of bona fide RNase H inhibitors with potent antiviral activity provides an example for challenges and opportunities in the field.
แจแแแคแแกแแ แแก แแแฌแแแแ
แแแแแฎแแ แแ แแฅแแแแ แแแ แ.
แแแคแแ แแแชแแ แฌแแแแแฎแแแกแแแ แแแแแแจแแ แแแแ
แกแแแ แขแคแแแแแ แแ แขแแแแแขแแแ
แแแแแแกแขแแแแ แแ Google Play Books แแแ Android แแ iPad/iPhone แแแฌแงแแแแแแแแแแกแแแแก. แแก แแแขแแแแขแฃแ แแ แแแแแฎแแ แชแแแแแแก แกแแแฅแ แแแแแแชแแแก แแฅแแแแก แแแแแ แแจแแแ แแ แกแแจแฃแแแแแแก แแแแชแแแ, แฌแแแแแแฎแแ แกแแกแฃแ แแแแ แแแแขแแแขแ แแแแแกแแแแ แแแแแแแก, แ แแแแ แช แแแแแแ, แแกแ แฎแแแแแ แแจแ แ แแแแแจแ.
แแแแขแแแแแ แแ แแแแแแฃแขแแ แแแ
Google Play-แจแ แจแแซแแแแแ แแฃแแแแฌแแแแแแแก แแแกแแแแ แแฅแแแแ แแแแแแฃแขแแ แแก แแแ-แแ แแฃแแแ แแก แแแแแงแแแแแแ แจแแแแซแแแแ.
แแแฌแแแแแแฎแแแแแแ แแ แกแฎแแ แแแฌแงแแแแแแแแแ
แแแแฅแขแ แแแฃแแ แแแแแแก แแแฌแงแแแแแแแแแแ แฌแแกแแแแแฎแแ, แ แแแแ แแชแแ Kobo eReaders, แแฅแแแ แฃแแแ แฉแแแแขแแแ แแแ แคแแแแ แแ แแแแแแขแแแแ แแแ แแฅแแแแก แแแฌแงแแแแแแแแจแ. แแแฎแแแ แแแแก แชแแแขแ แแก แแแขแแแฃแ แ แแแกแขแ แฃแฅแชแแแแแก แแแฎแแแแแ แแแแแแขแแแแ แคแแแแแแ แแฎแแ แแแญแแ แแ แแแฌแแแแแแฎแแแแแแแ.
